In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with ...

(“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for ...

Over the past few days, shares of Pheton have experienced an extraordinary and unexpected decline in its share price, which the Company believes may have been triggered by a speculative article ...

FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries. For more ...

Donnelly brings over 35 years of dining and restaurant expertise, including Thrive Restaurant Group, where he was a key principal in the development and execution of the HomeGrown breakfast and lunch ...

CEO, David Bailey added, “This launch marks our inaugural Pediatric Plating Platform and underscores our commitment to expanding the platform into the most comprehensive plating portfolio in pediatric ...

NeuroPace will continue to work with CMS on MS-DRG improvements and other reimbursement related topics. The company remains committed to ensuring that reimbursement policy keeps pace with clinical ...

The Company will reconvene its Annual General and Special Meeting of shareholders (the “Reconvened Meeting”) on August 22, 2025 at 10:00 a.m. (Eastern Time) to vote on the appointment of EY and the ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024; Dupixent ® global net sales (recorded by Sanofi) increased 22% to $4.34 billion ; EYLEA HD ...

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

Promising preclinical data for MDNA113 was presented at AACR 2025, highlighting its tumor-targeted design and strong anti-tumor activity in IL-13Rα2–positive tumor models, supporting development ...